CSTL
CASTLE BIOSCIENCES INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$35.34
−3.92%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$36.11
From 52W high−17.89%
Volume504416.00
Market cap$1.08B
P/E (TTM)—
P/S (TTM)3.0x
Div yield—
Key dataSep 18, 2026
Open
$36.11
From 52W high
−17.89%
Volume
504416.00
Market cap
$1.08B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−262.5x
P/E (TTM)
—
RSI (14)
65.2
MomentumView details →
1D Return
−3.92%
YTD Return
−8.11%
SummaryUpdated Jun 1, 2026
Castle Biosciences, Inc. (NASDAQ:CSTL) is a commercial-stage diagnostics company founded in 2007 and headquartered in Friendswood, Texas. The company went public in July 2019 and has established itself as a leading provider of gene expression profile (GEP) tests for various medical conditions, with a primary focus on dermatological cancers. Castle has evolved from a single-product company focused on melanoma testing to a diversified diagnostics platform serving dermatology, gastroenterology, and mental health markets through both organic growth and strategic acquisitions.
Similar companies
Latest newsMore news →
Castle Biosciences announced the publication of a decision modeling study showing its TissueCypher Barrett's Esophagus test improves risk-aligned management for patients with Barrett's esophagus.5d agoCastle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma.11d agoCastle Biosciences reported second-quarter 2026 revenue of $103.5 million, up 20% year-over-year.52d ago